EN
A major progress has been made in the systemic treatment of advanced melanoma over the last few years. Targeted therapy has proven highly active, which is reflected in the response rate as well as progression-free survival and overall survival times. The paper aims to summarize the current knowledge on the available BRAF and MEK inhibitors.